Autocrine signaling

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Autocrine signaling is when a cell releases a chemical signal that binds to receptors on the same cell, causing a response. In other words, the cell “talks to itself.” This is different from paracrine signaling (affecting nearby cells) and endocrine signaling (signals travel through the bloodstream to distant cells).

Simple examples:
- Monocytes can produce the cytokine interleukin-1 (IL-1) that then acts on the same cell to change its behavior.
- Activated T cells can release interleukin-2 (IL-2) which then binds to receptors on the same T cell, promoting its own growth and helping create a larger, self-stimulated T cell population.

Autocrine signaling in cancer:
- Cancer cells often use autocrine signals to grow, survive, and spread. By producing growth and survival factors themselves, tumors can sustain their own growth without external help.
- Wnt signaling: Disruptions in components like APC and Axin stabilize β-catenin, which travels to the nucleus and turns on cancer-related genes. This can also activate other pathways (like EGFR) that fuel tumor growth. In colorectal cancer, mutations in these components promote cancer, and in breast cancer, interfering with deregulated Wnt signaling can reduce cancer cell growth.
- IL-6: Autocrine IL-6 signaling is linked to lung and breast cancers. It often activates the STAT3 pathway, helping cancer cells survive and proliferate. HER2-overexpressing breast cancers frequently rely on an IL-6/STAT3 loop.
- VEGF: While VEGF is known for helping blood vessels grow, cancer cells can also use VEGF to signal on themselves, aiding survival and migration and contributing to invasive behavior.
- PDGFR signaling: Autocrine PDGFR loops support epithelial-mesenchymal transition (EMT), a process tied to metastasis. PDGFR activity is often associated with more invasive breast cancers.

Therapeutic implications:
- Targeting autocrine loops offers potential cancer treatments. This can include blocking Wnt ligand–receptor interactions, inhibiting IL-6/STAT3 signaling, or disrupting autocrine VEGF/VEGFR-2 signaling on cancer cells.
- Drugs like lapatinib can interfere with HER2-related autocrine loops; PDGFR-targeted strategies (including certain inhibitors) are explored to limit metastasis.
- Some approaches aim to turn on self-destructive signals in cancer cells, such as using compounds that promote TNFα-mediated apoptosis in an autocrine context.
- Cancers can develop resistance by relying on other autocrine loops (for example, non-small-cell lung cancer sometimes uses FGF loops to keep growing despite EGFR inhibitors; breast cancer can show tamoxifen resistance through STAT3-RANTES–mediated survival signals).

In short, autocrine signaling is self-stimulation by cells, and when it goes awry, it can help cancers grow and spread. Understanding these self-signaling loops helps researchers develop targeted therapies to interrupt them.